uniQure to Participate in Multiple Upcoming Industry Conferences in February
January 31 2020 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in February:
- 13th Annual Congress of the European Association for
Hemophilia and Allied Disorders (EAHAD), February 5 – 7, The Hague,
the Netherlands.• uniQure will deliver 7
presentations on the development of its gene therapy candidates
etranacogene dezaparvovec for hemophilia B, AMT-180 for hemophilia
A, and its technology platform.• Further details on the
company’s presentations will follow closer to
conference.
- 16th Annual WORLD Symposium, February 10 – 13, Orlando,
FL.• Ying Poi Liu, Ph.D., senior scientist at uniQure,
will present on the development of an AAV5-based gene therapy for
Fabry disease, on Tuesday, February 11, from 4:30 – 6:30 p.m.
ET.
- CHDI 15th Annual Huntington’s Therapeutics Conference,
February 22 – 25, Palm Springs, CA.• uniQure will
deliver 5 presentations on the development of AMT-130, the
company’s AAV-gene therapy candidate for the treatment of
Huntington’s disease.• Further details on the company’s
presentations will follow closer to the conference.
- 64th Annual Meeting of the Society of Thrombosis
and Haemostasis Research – GTH 2020, February 18 – 21, Bremen,
Germany.• Professor Wolfgang Miesbach, M.D., Ph.D.,
of the University Hospital Frankfurt in Germany, will present
12-month follow-up data on the company’s gene therapy candidate
etranacogene dezaparvovec in hemophilia B, as well as four-year
follow-up data on AMT-060, also in patients with hemophilia B.
- 9th Annual SVB Leerink Global Healthcare Conference,
February 25 – 27, New York City.• Matt Kapusta, chief
executive officer at uniQure, will participate in a fireside chat
with research analyst Joseph Schwarz, on Tuesday, February 25,
from 2:30 – 2:55 p.m. ET. The live webcast of the corporate update
can be accessed through the link displayed in the Investor section
of the uniQure website. The webcast replay will be available for at
least 72 hours following the live event. • Members of
uniQure’s management team will participate in one-on-one investor
meetings throughout the day on Tuesday, February 25.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024